The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)

首次发布于 2015 年 3 月 19 日

External ValidatIon Trial of ASTER Trial

计划入组 255 人 · 首次发布于 2011 年 4 月 11 日

The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease

首次发布于 2015 年 4 月 21 日

MAP2K4 inhibitors (Astex Pharmaceuticals)

p53 inhibitor(Astex Pharmaceuticals/MSD)

4-phenyl-2-phenylaminopyridine analogs(Astex Phamaceutical)

ASTEX PHARMACEUTICALS INC.

United States

ASTEX PHARMACEUTICALS, INC.

United States

Astex and Genentech Enter $490M+ Collaboration to Target Cell-Cycle Regulator in Breast Cancer

Astex Pharmaceuticals Highlights Preclinical and Clinical Advances at EORTC-NCI-AACR Symposium

Mosaic Therapeutics Acquires Two Clinical-Stage Oncology Programs from Astex to Develop Novel Combination Therapies